An AI publication
For readers who want to understand important AI developments and keep following the questions that matter.
Our articles start from AI podcast conversations and the research papers and articles they cite, with links to the original material.
A briefing reports one development at a point in time. We may correct or clarify it later; a new development gets a new briefing. How our formats work
An AI-scripted, AI-voiced episode, labelled as AI, kept 40 to 50% of listeners to the end, says The Diary of a CEO's host, who argues informational podcasting is substitutable while in-person experiences will command a premium.
David Friedberg argued AI can screen a million protein ideas on computers to find ones that might reverse cell aging, without a full theory of the cell. The eye work he cited has reached a first safety trial in people, not restored sight.
David Friedberg argued that open-weight AI models will keep value from pooling in two or three labs, betting someone with zero net worth today will become a billionaire within 10 years by building on downloaded open-source AI.
Investor David Friedberg argued AI grows companies and hiring rather than shrinking payrolls, but said his view could fail if displaced workers don't see new opportunities and choose to move to them.
Tim Sweeney tweeted that Elon Musk's predicted 100x gain in intelligence per gigabyte has come true; Musk says specialist AIs add another 100x. Dave asks how 10,000 agents would work together; Alex says specialists are really sparsification.
Peter Diamandis said a Unitree humanoid built in three months ran 12.66 m/s, above Bolt's 12.4. Salim Ismail urged non-human designs, Alexander Wissner-Gross bet on general-purpose bodies, and Emad Mostaque predicted street limits on extreme robots.
Peter Diamandis, after meeting SK hynix and Solidigm leaders, argued memory, not GPUs, now limits AI. Panelists blamed new AI workloads and bust-wary suppliers, and floated etching model weights into chips as a possible fix.
GenBio's AIDO Cell simulates a human cell that remembers successive edits and drugs. For now it helps prioritize experiments in two cell lines; lab validation of its novel predictions is underway. A Moonshots panelist called it the end of medicine.
Merck and Moderna said personalized mRNA therapy intismeran autogene plus Keytruda beat Keytruda alone on melanoma recurrence-free and distant-metastasis-free survival in a 1,137-patient phase 3 interim analysis. No effect sizes were released.
Uber is investing in Zipline and adding its drones to Uber Eats, targeting one million deliveries a day by end-2029. Moonshots panelists saw it as a test of Uber aggregating demand while suppliers, who could sell direct, own the robots.
Dave Blundin of Link Ventures says one bad coding idea can spread through all 5,000 of his identical AI agents, costing roughly $50,000 in tokens unless he rewinds them. Panelists linked it to a paper on "mind viruses" spreading between agents.
Anthropic is reportedly weighing super-voting shares to keep founders in control after its IPO, per The Information. A Moonshots panel splits over who really steers a frontier AI lab: founders, its benefit trust or market pressure.
Browse by tag